In a study of 26 prolactinomas, bromocriptine was initiated in all cases, and conversion to quinagolide
or cabergoline was made due to development of intolerance or resistance to bromocryptine (13).
Among currently available dopamine agonists, cabergoline, quinagolide
and bromocriptine are the most common drugs that should be used for prevention of both early and late OHSS.
Dopamine agonists like bromocriptine, cabergoline and quinagolide
administration restores normal ovarian function and is the first line treatment for most patients wishing to conceive.
It has been reported that treatment of prolactinoma with dopamine 2 receptor agonists such as bromocriptine, lisuride, cabergoline, and quinagolide
may provoke the disease .
Bromocriptine, cabergoline, quinagolide
, and amantadine are some common dopamine agonists.
Hormone levels and tumour size response to quinagolide
and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
, binding to dopamine D2 receptor, down-regulated VEGF/VEGFR2, inhibited neoangiogenesis, and reduced the size of active endometriotic lesions .
Additionally, some studies emphasize the effects of bromocriptine, cabergoline, and quinagolide
therapies in the treatment of FSHoma (16).
Several dopamine agonists are currently available for the treatment of hyperprolactinemia, including bromocriptine and cabergoline in the USA and, additionally, quinagolide
in the UK and most other European countries (2,4).
Other drugs used for treatment of prolactinomas that have not been approved by the FDA include mesylate, lisuride and quinagolide
(Shimon & Melmed, 1998).
(D(2/3) agonist), ropinirole (D(2/3/4) agonist), SKF 38393 (D(1/5) agonist), AR-C68397AA (Viozan) (dual D(2)/B(2) agonist) and dopamine all inhibit hypertonic saline induced depolarization by approximately 50% (14).